Ticker: TSX – TOS
Shares Outstanding: 82,617,989
QUÉBEC CITY, July 24, 2015 /CNW Telbec/ - TSO3 Inc. (TSX: TOS) ("TSO3" or the "Corporation") an innovator in sterilization technology for medical devices in healthcare settings, today announced that the Company has received purchase orders for multiple devices from the US. The orders are the result of the collaborative relationship between Getinge Infection Control, its sales and service provider, and the Company.
"Finally!" exclaimed R.M (Ric) Rumble, President and CEO.
"Our Vision is to Create the Improved Standard in Healthcare Sterile Reprocessing™; after spending years in development and working our way through the regulatory demands outlined when launching a new and novel technology we have now received the first orders." Mr. Rumble proudly stated. "Every week the list of identified customer targets grows and our pipeline of quotations increases. We feel very good about the product's initial launch and are working to implement even more ways to increase market awareness for our superior sterilizer. We are letting our shareholders know about these first orders as they have expressly requested this information, however, moving forward, we will hold such information for quarterly updates. Needless to say, we are very excited to add these new US accounts to our base of Canadian customers." concluded Mr. Rumble.
About the STERIZONE® VP4 low temperature sterilizer
The STERIZONE® VP4 Sterilizer developed by TSO3 is a dual sterilant, low temperature sterilization system that utilizes vaporized hydrogen peroxide (H2O2) and ozone. Its single cycle can sterilize a large number and wide range of compatible devices, thereby allowing for a cost effective and error-free sterilization process. TSO3's unique Dynamic Sterilant Delivery SystemTM automatically adjusts the quantity of injected sterilant based on the load composition, weight and temperature. With its large 75 lb load capacity and a short cycle time, the STERIZONE® VP4 Sterilizer can enhance throughput and lower sterilization cost. The STERIZONE® VP4 Sterilizer was cleared for commercialization in the United States in December 2014.
More information about the STERIZONE® VP4 Sterilizer is available through TSO3's website, under the Products section: http://www.tso3.com/en/products/sterizone-vp4/
Founded in 1998, TSO3's activities encompass the sale, production, maintenance, research, development and licensing of sterilization processes, related consumable supplies and accessories for heat-sensitive medical devices. The Company designs products for sterile processing areas in the hospital environment that offer an advantageous replacement solution to other low temperature sterilization processes currently used in hospitals. It also offers services related to the maintenance of sterilization equipment and compatibility testing of medical devices with such processes.
For more information about TSO3, visit the Company's Web site at www.tso3.com.
The statements in this release and oral statements made by representatives of TSO3 relating to matters that are not historical facts (including, without limitation, those regarding the timing or outcome of any financing undertaken by TSO3) are forward-looking statements that involve certain risks, uncertainties and hypotheses, including, but not limited to, general business and economic conditions, the condition of the financial markets, the ability of TSO3 to obtain financing on favourable terms and other risks and uncertainties.
The TSX has neither approved nor disapproved the information contained herein and accepts no responsibility for it.
SOURCE TSO3 Inc.
For further information: R.M. (Ric) Rumble, President and CEO, 418 651-0003, Email: [email protected]